Edition:
United States

Profile: Acorda Therapeutics Inc (ACOR.O)

ACOR.O on Nasdaq

27.20USD
20 Oct 2017
Change (% chg)

$0.50 (+1.87%)
Prev Close
$26.70
Open
$26.90
Day's High
$27.60
Day's Low
$26.50
Volume
619,321
Avg. Vol
792,624
52-wk High
$33.00
52-wk Low
$13.60

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.

Company Address

Acorda Therapeutics Inc

420 Saw Mill River Rd
ARDSLEY   NY   10502-2605
P: +1914.3474300
F: +1914.3474560

Company Web Links